**Name of Journal:** *World Journal of Critical Care Medicine*

**Manuscript NO:** 65898

**Manuscript Type:** REVIEW

**Orosomucoid-like protein 3, rhinovirus and asthma**

Zhang YM. *ORMDL3*, Rhinovirus and Asthma

You-Ming Zhang

**You-Ming Zhang,** Section of Genomic and Environmental Medicine, National Heart and Lung Institute, Molecular Genetics Group, Division of Respiratory Sciences, Imperial College London, London SW3 6LY, United Kingdom

**Author contributions:** Zhang YM wrote, read and approved this manuscript.

**Corresponding author: You-Ming Zhang, PhD, Lecturer,** Section of Genomic and Environmental Medicine, National Heart and Lung Institute, Molecular Genetics Group, Division of Respiratory Sciences, Imperial College London, Dovehouse Street, London SW3 6LY, United Kingdom. y.zhang@imperial.ac.uk

**Received:** March 17, 2021

**Revised:** April 16, 2021

**Accepted:** August 23, 2021

**Published online:** September 9, 2021

**Abstract**

The genetic variants of orosomucoid-like protein 3 (*ORMDL3*) gene are associated with highly significant increases in the number of human rhinovirus (HRV)-induced wheezing episodes in children. Recent investigations have been focused on the mechanisms of *ORMDL3* in rhinovirus infection for asthma and asthma exacerbations. *ORMDL3* not only regulates major human rhinovirus receptor intercellular adhesion molecule 1 expression, but also plays pivotal roles in viral infection through metabolisms of ceramide and sphingosine-1-phosphate, endoplasmic reticulum (ER) stress, ER-Golgi interface and glycolysis. Research on the roles of *ORMDL3* in HRV infection will lead us to identify new biomarkers and novel therapeutic targets in childhood asthma and viral induced asthma exacerbations.

**Key Words:** Asthma;Intercellular adhesion molecule 1; Orosomucoid-like protein 3; Rhinovirus infection; Sphingolipids

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhang YM. Orosomucoid-like protein 3, rhinovirus and asthma. *World J Crit Care Med* 2021; 10(5): 170-182

**URL:** https://www.wjgnet.com/2220-3141/full/v10/i5/170.htm

**DOI:** https://dx.doi.org/10.5492/wjccm.v10.i5.170

**Core tip:** Orosomucoid-like protein 3 (*ORMDL3*)gene has been identified to have a strong association with childhood asthma. The gene has also been found to link with human rhinovirus (HRV) infection in children. ORMDL3 mediates HRV infection through regulating expression of HRV receptor intercellular adhesion molecule 1, metabolisms of ceramide and sphingosine-1-phosphate, endoplasmic reticulum (ER) stress, ER-Golgi interface and glycolysis.

**INTRODUCTION**

Asthma is one of the major health and economic burdens in the world. It is a syndrome characterised by airway inflammation and intermittent symptoms of wheeze and shortness of breath. The combinations of genetic and environment factors cause the disease[1]. The disease has a high prevalence as well as a chronic relapsing course. Acute asthma exacerbations are the major cause of high morbidity and mortality whilst severe asthma remains difficult to treat.

In 2007, single nucleotide polymorphisms (SNPs) flanking *ORMDL3* gene on chromosome 17 were found to be highly associated with asthma in a genome-wide association study[2]. This association has subsequently been replicated in many studies, including a multi-ancestry global meta-analysis[3]. The locus has also been found to be associated with many asthma related traits. Expression quantitative trait loci analysis revealed that SNPs in the locus regulate transcript levels of potential asthma genes[4]. The locus is associated with eosinophil account in blood and fractional exhaled nitric oxide levels[5]. *ORMDL3* locus is now considered as the major predisposing factor for childhood-onset asthma. Children with enhanced transcription genotypes at *ORMDL3* locus have been found to have significant increases in the number of wheezing illnesses. Early symptomatic human rhinovirus (HRV) infection is a risk factor for subsequent asthma, and the infection causes nearly two thirds of childhood asthma exacerbations[6]. The genetic variants on chromosome 17q21 and early environmental tobacco smoke exposure enhance the association between early respiratory infection and early-onset asthma. Individuals who were homozygous for the risk alleles at the *ORMDL3-*associated SNPs had a greater than twofold difference in the association between early viral infection and asthma[7].

The symptoms of virial respiratory infection are most caused by rhinoviruses[8]. More than twenty years ago, as the development of molecule techniques of identifying pathogens, rhinoviruses were found to be the major virus types in mild and severe wheezing illness in all age groups of children, but particularly over one year of age[9]. The most common symptoms for HRV infection include rhinorrhea, sore throat, nasal congestion, sneezing, cough, and headache[10]. HRV infection is also the major cause for exacerbations of chronic obstructive pulmonary disease (COPD) and cystic fibrosis[11,12]. In this review, I will update the recent developments for research on potential mechanisms that *ORMDL3* regulates HRV infection in asthma. I will also discuss the research strategies to identify novel therapeutic targets for HRV infection in human airway diseases.

**HRVS**

HRVs were identified in the 1950s for exploring the causes of the common cold[13,14] and are positive-sense, single-stranded-RNA (ssRNA) viruses with approximate 7200 base pairs. The viruses belong to the family *Picornaviridae* and the genus enterovirus. The genome consists of a single gene whose translated a protein peptide. The protein peptide then is cleaved by protease to 11 proteins[15]. Among them, four proteins including VP1, VP2, VP3, and VP4 consist the viral capsid encasing the RNA genome, while the rest are non-structural proteins (2A, 2B, 2C, 3A, 3B, 3C, 3D) for functioning in viral replication and assembly[11].

**SEROTYPES AND PHYLOGENETICS OF HRVS**

Serotypes are defined as groups within a single species of microorganisms that share distinctive surface structures. The four capsid proteins of HRVs provide the virion an icosahedral structure, with a canyon in VP1 of attachment to cell surface receptors. More than 90% of known HRV serotypes are classified as major group, utilizing the cell surface receptor intercellular adhesion molecule 1 (ICAM1), while the minor group HRVs attach cells via the low-density lipoprotein receptor (LDLR). Some of the major-group HRVs can use heparan sulphate as an additional receptor for cell attachment and entrance[16-18]. More than 100 serotypes of HRVs were discovered and the diversities of serotypes of HRVs make the specific vaccine against the virus infection very difficult to create.

Phylogenetics is the study of the evolutionary relatedness among organisms. Molecular phylogenetics applies sequence data to infer these relationships. Based on sequence, phylogenetic sequence HRVs are classified into three species, HRV-A, HRV-B and HRV-C. HRV-A (containing 77 serotypes) and HRV-B (containing 30 serotypes) species can be cultured in normal cells culture[19]. HRV-C strains do not grow in standard cell culture although the genomic organization of HRV-C strains is similar to that of HRV-A and HRV-B. At least 50 different types of HRV-C have been identified[20,21]. In 2011, HRV-C was found to grow in sinus mucosal tissue, and the species used a distinct cell attachment mechanism[22]. It was then identified that HRV-C entrance of cells by cadherin related family member 3 (CDHR3) receptor[23].

**RECEPTORS FOR HRVS**

***ICAM1***

ICAM1 is a cell surface ligand for the lymphocyte function antigen 1 adhesion receptor[24,25]. It was cloned and sequenced in 1988[26]. ICAM1 is a 90 kD inducible surface glycoprotein. It promotes adhesion in immunological and inflammatory reactions. In 1989, ICAM1 was then found as a receptor for HRVs major group entrance to the cell by using ICAM1 monoclonal antibody blocking the cytopathic effect in HeLa cells[27]. It binds to integrins of CD11a/CD18, or CD11b/CD18 and it is a prominent molecule in leukocyte trafficking, immunological synapse formation, and cellular immune responses[28]. ICAM1 is expressed on essentially all leukocyte subsets, epithelial cells, endothelial cells, fibroblasts, platelets and others[29]. For most cell types under non-inflammatory conditions, ICAM1 expression is constitutively low, it is detectable only on endothelial cells[30,31]. On the condition of stimulations of IL-1β, TNF-α, IFN-γ and other cytokines, ICAM1 can increase expression in a cytokine- and cell-specific manner[28,32]. Soluble ICAM1 can be detectable in the plasma and it increases in patients with various inflammatory conditions. HRVs upregulate membrane-bound ICAM1 expression via a NFKB-dependent mechanism[33] and downregulate the release of soluble ICAM1[34]. ICAM1 upregulation was also founded *in vivo* on nasal epithelial cells in an experimental HRV39 infection of healthy volunteers[35].

***LDLR***

LDLR family members were identified as the receptors for minor group rhinoviruses, that consists of only 12 known HRV-A types. The members are evolutionarily ancient proteins that are expressed on the surface of many cell types[36].The LDLR family includes at least three members that can bind and internalize HRV as the LDLR, the LDLR related protein and the very low density lipoprotein receptor. Receptors in this family are recognized by the presence of several structural modules and overall similar domain arrangements. The structural characters include ligand-binding repeats, epidermal growth factor precursor repeats, a single transmembrane domain, β-propeller modules and a relatively short cytoplasmic tail[37]. LDLR uptakes its natural ligand, cholesterol-carrying lipoprotein particles by endocytosis, and their release upon delivery to the low pH milieu of the endosome[38]. The cytoplasmic tail of the LDLR family members contains specific motifs that can interact with a number of cytoplasmic adaptor and scaffold proteins to mediate signal transduction[37].

***CDHR3***

CDHR3 is a member of cadherin superfamily of transmembrane glycoproteins. The biological function remains unclear. Other members of this family such as desmosomal cadherins and classical cadherins are responsible for communications between identical cells through calcium-dependent interactions. Protocadherins are involved in neuronal plasticity and tissue development[39]. Cadherins are the major components of adherens junctions and desmosomes and also have other functions including signalling and mechanical transduction[40].

**OTHER RECEPTORS**

Some major-group HRVs also use heparan sulphate as an additional receptor[11]. Airway epithelial cells infected by HRV can detect and respond to the virus via toll-like receptors (TLRs) to activate signalling pathways and generate pro-inflammatory cytokines and type I interferons[41]. The HRV6 capsid was found to be recognized *via* TLR2. With HRV6 ssRNA internalization, the virus genome is recognized by endosomally located TLR7 and TLR8[42].

**HRV INFECTION AND RESPIRATORY DISEASES**

HRVs not only are highly associated with asthma, COPD and cystic fibrosis, the viruses also have been found to cause upper respiratory infection including common cold, acute otitis media and rhinosinusitis. They can be responsible for lower respiratory infection including coup, bronchiolitis, community-acquires pneumonia. Based on antigenic cross-reactivity in serum neutralization tests, clinical isolates of HRV-A and HRV-B identified by 1987[43] were classified into 100 serotypes. More recently isolated A and B types were assigned solely on sequence identity criteria[44], HRV-A and HRV-C isolates are more virulent in infants, and are more likely to cause exacerbations of childhood asthma compared to HRV-B[45,46]. HRVs cause respiratory illness throughout the world and throughout the year. Longitudinal studies of the epidemiology and clinical features reported a peak incidence of HRV infection in the early fall and a smaller peak in the spring[47]. HRVs are the most common cause of respiratory viral illness during the spring, summer, and fall months. Infections with influenza virus and RSV predominate in the winter[11]. Not like other respiratory viruses, such as influenza virus and respiratory syncytial virus that cause cytopathology of the upper respiratory tract; for HRV infection, the epithelial cell lining and borders remained structurally intact although the cells were sloughed[48]. However, HRVs can still cause damage of epithelial cell barrier function[49], which can facilitate the transmigration of bacteria and exposing basolateral epithelial cell receptors such as TLRs[50]. Direct infection of the lower airway or the stimulation of inflammatory, immunological, or neurogenic mechanisms are the mechanisms of low airway dysfunction or diseases. Impaired innate and acquired immune responses for Th1 responses were found in asthma patients[51,52]. Epidermal growth factor (EGF) promotes viral replication by suppressing antiviral related immune mediators and has prominent role of EGF in the immune response to HRVs[53]. There are currently no approved antiviral therapies for HRVs, and treatments majorly are supportive.

***ORMDL3* AND HRV INFECTION**

After the association of the polymorphism of *ORMDL3* and asthma has been established[2,54], the subsequent research found it was linked to the frequency of rhinoviral wheezing illness and then subsequent development of childhood asthma[6]. Inhalation allergen could induce a significant increase in levels of expression of *ORMDL3* in airway epithelium and in macrophages in an allergen-induced mouse model[55]. The research on the roles of *ORMDL3* in HRV infection just begun and most results were from mouse models and cellular models. In a transgenic mice that express increased levels of human *ORMDL3* showed that *ORMDL3* contributes to antiviral defence to HRV infection through pathways that may include interferons (IFNα, IFNβ, IFNλ), OAS, and RNAse L[56]. In a human epithelial cell model, *ORMDL3* was found to be required in supporting HRV replication *via* SPT inhibition[57]. Human *ORMDL3* is a trans-membrane protein anchoring in the endoplasmic reticulum (ER). The ER is the site responsible for protein folding, storage of calcium and synthesis of lipids. ER stress can reduce the capacity for protein folding and thereby regulate cellular responses to inflammation. *ORMDL3* facilitates the unfolded protein response to cellular stress by influencing ER calcium ATPase and ER-mediated Ca2+ flux[58]. It interacts with the serine SPT enzyme complex in sphingolipid synthesis especially for ceramide and sphingosine-1-phosphate (S1P) levels[59]. *ORMDL3* could work in multiple pathways in regulating HRV infection[60].

**THE POTENTIAL REGULTATING MECHANISMS OF *ORMDL3* FOR HRV INFECTION**

***Regulating ICAM1 expression levels***

To explore the roles of *ORMDL3* in epithelial cells, our lab established *ORMDL3* knockdown and *ORMDL3* over-expression immortalised epithelial cell lines and human primary bronchial epithelial cells. Knockdown of *ORMDL3* led to a steroid-independent reduction of both IL8 and IL6 release and reduced ER stress after stimulation of IL1β. Global gene expression analysis revealed that knockdown of *ORMDL3* resulted in the reduction of expression of genes regulating host-pathogen interactions, stress responses and ubiquitination. Metabolomic analyses showed that knockdown led to changes in levels of metabolites integral to glycolysis. Additionally, knockdown increased concentrations of the immune mediators such as ceramides. The multiple effects of *ORMDL3* in cellular inflammation are consistent with its substantial genetic influence on childhood asthma. Of particular interest is that *ORMDL3* knockdown strongly reduced expression of the HRV receptor ICAM1 during the inflammatory response[61]. In an eosinophil *ORMDL3* knockdown experiment, a significant reduction in adhesion of *ORMDL3*-siRNA-treated eosinophils to ICAM1 was noted compared to control-siRNA-treated cell, and *ORMDL3* regulates eosinophil trafficking, recruitment[62]. The results indicate *ORMDL3* can regulate ICAM1 expression level, then influence HRV infection in human epithelial cells and immune cells.

***Regulating ER stress***

*ORMDL3* is a protein anchored on the ER of the cell. The ER in eukaryotes is the site of protein folding as well as the site for synthesis of lipids and sterols and the storage of free calcium. Stresses on ER can therefore lead to an imbalance between the capacity for protein folding and the demand. It is linked to cellular responses to inflammation. ER stress happens when the capacity of the ER to fold proteins becomes saturated. ER stress induces the evolutionarily conserved signalling pathways, defined as the unfolded protein response, which compromises the stimulus and then determines whether the cell die or survives. It may be caused by factors that impair protein glycosylation, disulphide bond formation, mutations or overexpression. We previously experiments showed *ORMDL3* was a regulator of ER stress in mouse and in cellular models[61,63]. There are three signal transduction pathways for ER stress, including protein kinase RNA-like ER kinase (PERK), activating transcription factor 6 (ATF6) and inositol-requiring enzyme 1 (IRE1)[64]. Both non-structural protein 2B and HRV16 can induce an ER stress response through the PERK and ATF6 pathways[65]. Different viruses can modulate these mechanisms to escape the host immune response to their advantages[66].

***Regulating sphingolipids metabolism***

*ORMDL3* was first identified as a regulator for *de nove* synthesis of sphingolipids in cells[59]. Sphingolipids are amphipathic molecules derived from sphingosine. Ceramides are the central molecules of sphingolipids metabolism. Sphingosine phosphorylation leads to S1P. S1P and ceramides mediate cell proliferation, survival, apoptosis, differentiation and cell-cycle arrest[67,68]. Ceramide-rich platforms affect signalling cascades in immune cells, including activation of B cells, bacterial pathogen infection. S1P drives the differentiation of immune cells, inducing changes in their phenotypes and regulating production of eicosanoids and inflammatory cytokines[69]. Clinical studies showed that sphingosines and ceramide were increased in asthmatic airways[70]. Sphingolipid pathways offer many opportunities for pharmacologic intervention and investigations of anti-inflammatory effects have been centred on S1P[69]. Importantly, modulating sphingolipids is known to affect ICAM1 expression in epithelial cells (keratinocytes)[71] so that the ICAM1/sphingolipid axis may provide novel prevention strategies for viral-induced childhood asthma. Ceramide levels were greatly affected by the expression of *ORMDL3* in mouse model[72,73] and in airway epithelial cells[61]. Decreased sphingolipid synthesis was found in children with 17q21 asthma–risk genotype[74]. Ceramides activate protein phosphatase 2 to cause endothelial dysfunction[75]. Ceramides suppress the electron transport chain to induce production of reactive oxygen species in mitochondria[76]. Imbalance of ceramides and impaired TLR4-mediated autophagy were reported in an *ORMDL3*-overexpressing mouse model[77]. S1P receptors inhibition was found to be critical for immunomodulation. S1P can directly suppress TLR mediated immune response from T cells. S1P extracellular actions are mediated by its interaction with a family of five specific G-protein-coupled receptors, S1P1-S1P5[78]. Ceramide kinase and sphingosine kinases control many aspects of cell physiology, including inflammatory response and cell survival[79]. S1P was found to be important in immunoglobulin E-mediated mast cell migration and degranulation[80], allergic asthma, and secretion of inflammatory cytokines[81]. In allergic models of asthma, S1P and ceramide are important signalling molecules for airway hyperreactivity, mast cell activation, and inflammation[82].

***Regulating ER-Golgi interface***

Golgi apparatus is a cell organelle that facilities process and package proteins and lipid molecules to be exported from the cell. Infection of human epithelial cells with several rhinovirus strains triggers a rapid activation of the acid sphingomyelinase. The activity of the acid sphingomyelinase results in the formation of ceramide in the cell membrane. Acid sphingomyelinase is also a key molecule for the infection of human cells with rhinoviruses[83,84]. The ability of replicating picornaviruses to influence the function of the secretory pathway has important implications for host defence. Individual non-structural protein B2 and HRV16 can both fragment the Golgi apparatus and block secretion, whereas viral infection fragments the Golgi apparatus without blocking secretion[84]. HRV uses a phosphatidylinositol 4-phosphate/ cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface[85]. *ORMDL3* regulates ER stress and lipid membrane synthesis and that could directly influence ER-Golgi interface to response HRV infection.

***Regulating glycolysis***

Glycolysis is a cytoplasmic pathway that breaks down glucose into two three-carbon compounds and generates energy. Glucose is trapped by phosphorylation, with the assistance of the enzyme hexokinase. Glycolysis is one of major energy-yielding pathways that glucose is converted into pyruvate in the glycolytic process[86]. Recent research showed that IL-1β/inhibitory κB kinase ε signalling plays an important role in house dust mite-induced glycolysis[87]. Aerobic glycolysis is increased in asthma, which promotes T cell activation. Inhibition of aerobic glycolysis blocks T cell activation in asthma[88]. Lactic acid (LA), pyruvic acid (PA) and LA/PA are increased in the process. Increased glycolysis and anaerobic respiratory muscle glycolysis during airways obstruction may be important in these changes[89]. The early asthmatic response has been found to be associated with calcium binding, glycolysis and mitochondria activity in rats[90]. Glycolysis of target cells was found as an intrinsic host factor that determines the extent of norovirus replication[91]. *ORMDL3* deficient epithelial cells showed abnormality of glycolysis[61] and that can regulate HRV replication in cytoplasm.

The possible regulating mechanisms of *ORMDL3* for HRV infection were listed in the Table 1.

**THE POTENTIAL THERAPEUTIC TARGETS FOR HRV INFECTION**

***Targeting ORMDL3/ICAM1 and sphingolipid pathways***

Many compounds work in the *ORMDL3*/ICAM1 and sphingolipid pathways. Myriocin is the potent inhibitor of SPT, the rate-limiting enzyme of first step in sphingosine biosynthesis. Recent research showed that SPT activity was increased by house dust mite exposure and that *de novo* sphingolipids synthesis can be effectively inhibited by myriocin both *in vitro* and *in vivo*[92]. Fumonisin B1 has a structural similarity to the cellular sphingolipids, and this similarity can disturb the metabolism of sphingolipids by inhibiting the enzyme ceramide synthase[93]. Fumonisin B1 can attenuate nitrotyrosine formation and oxidative/nitrosative stress, epithelial cell apoptosis, and airway inflammation to improve histopathological abnormalities[94]. Tamoxifen inhibits ceramide glycosylation[95]. Tamoxifen treatment in horses with induced acute pulmonary inflammation promoted early apoptosis of blood and BALF neutrophils, reduction in BALF neutrophils[96]. Fingolimod is an FDA approved immunomodulatory drug for treating multiple sclerosis by down regulating S1P receptor[97]. FTY72 acts as a high-affinity agonist at the G protein-coupled sphingosine 1-phosphate receptor-1 (S1P1) on thymocytes and lymphocytes to induce aberrant internalization of the receptor[98]. There are numerus inhibitors in sphingolipid and ceramide synthesis pathways[99,100], investigating these inhibitors provide the potential therapeutic tools to influence HRV infection. HRV-induced inflammatory responses are inhibited by phosphatidylserine containing liposomes[41].

***Research models of epithelial cells and finding new targets for HRV infection***

Research models to investigate interactions between human host (genetic) and environmental factors are underdeveloped. These interactions are very important for chronic respiratory diseases such as asthma. We now know that airway microorganisms play important roles in health and in chronic respiratory diseases, but how the host and microorganisms function remain unclear. The airway epithelium has previously been investigated with monolayer models, where undifferentiated epithelial cells are grown underneath culture media. Cells that are grown at an air liquid interface (ALI) can be fully differentiated. ALI becomes a realistic and efficient tool to study cell-cell interaction studies following exposure to aerosolized or gaseous form of air pollutants[101], bacteria[102] and virus[103]. Primary bronchial epithelial cells cultured at ALI leads to differentiate into respiratory epithelium consisting of goblet cells, ciliated cells, basal cells and club cells. ALI culture system is also considered as a feasible approach to implement the "3R principle"-replacement, reduction, Recently epithelial ALI culture was successfully applied with HRV infection[104]. ALI cultures contain more epithelial components and are closer to normal human airways. In a further development, three-dimensional (3D) cultured lung tissues known as spheroids[105] other cell types such as fibroblasts are included. 3D culture with epithelial cells could help to provide highly predictive drug tests for patient-specific conditions in the near future[106]. The advantages of the ALI and 3D human lung spheroid models for interaction study are listed in Table 2. Importantly, ALI and 3D human lung spheroid models can be co-cultured with microorganisms relevant to asthma. These models provide an alternative of animal research and will reduce the use of animals in experiments as animal model for genetic modify are complicated procedures and time-consuming. Genetic animal model usually takes many generations of breeding and screening. For example, we identified *DPP10* as a novel gene underlies asthma in 2003[107], we created a *Dpp10* mutagenesis mouse tool and finally finished functional studies in 2018[108]. The use of genetic modified epithelial cells such as specific gene knockout cells not only provides a powerful platform to study the interaction between gene and environment but also to identify the novel therapeutic targets such as for HRV infection.

**CONCLUSION**

*ORMDL3* emerged as a key molecule to regulate HRV infection in human respiratory epithelial cells. It influences the expression of HRV receptor ICAM1, the ER stress pathway, ceramide and S1P metabolism, ER-Golgi interface and glycolysis process. ORDM3/ICAM1 and sphingolipid metabolism provide novel therapeutic targets for HRV infection. Epithelial models with ALI and other 3D cultures will have prominent roles to identify the druggable molecules for clinical treatment of asthma, COPD, cystic fibrosis and other respiratory conditions induced by HRVs.

**REFERENCES**

1 **Zhang Y**, Moffatt MF, Cookson WO. Genetic and genomic approaches to asthma: new insights for the origins. *Curr Opin Pulm Med* 2012; **18**: 6-13 [PMID: 22112999 DOI: 10.1097/MCP.0b013e32834dc532]

2 **Moffatt MF**, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, Depner M, von Berg A, Bufe A, Rietschel E, Heinzmann A, Simma B, Frischer T, Willis-Owen SA, Wong KC, Illig T, Vogelberg C, Weiland SK, von Mutius E, Abecasis GR, Farrall M, Gut IG, Lathrop GM, Cookson WO. Genetic variants regulating *ORMDL3* expression contribute to the risk of childhood asthma. *Nature* 2007; **448**: 470-473 [PMID: 17611496 DOI: 10.1038/nature06014]

3 **Demenais F**, Margaritte-Jeannin P, Barnes KC, Cookson WOC, Altmüller J, Ang W, Barr RG, Beaty TH, Becker AB, Beilby J, Bisgaard H, Bjornsdottir US, Bleecker E, Bønnelykke K, Boomsma DI, Bouzigon E, Brightling CE, Brossard M, Brusselle GG, Burchard E, Burkart KM, Bush A, Chan-Yeung M, Chung KF, Couto Alves A, Curtin JA, Custovic A, Daley D, de Jongste JC, Del-Rio-Navarro BE, Donohue KM, Duijts L, Eng C, Eriksson JG, Farrall M, Fedorova Y, Feenstra B, Ferreira MA; Australian Asthma Genetics Consortium (AAGC) collaborators, Freidin MB, Gajdos Z, Gauderman J, Gehring U, Geller F, Genuneit J, Gharib SA, Gilliland F, Granell R, Graves PE, Gudbjartsson DF, Haahtela T, Heckbert SR, Heederik D, Heinrich J, Heliövaara M, Henderson J, Himes BE, Hirose H, Hirschhorn JN, Hofman A, Holt P, Hottenga J, Hudson TJ, Hui J, Imboden M, Ivanov V, Jaddoe VWV, James A, Janson C, Jarvelin MR, Jarvis D, Jones G, Jonsdottir I, Jousilahti P, Kabesch M, Kähönen M, Kantor DB, Karunas AS, Khusnutdinova E, Koppelman GH, Kozyrskyj AL, Kreiner E, Kubo M, Kumar R, Kumar A, Kuokkanen M, Lahousse L, Laitinen T, Laprise C, Lathrop M, Lau S, Lee YA, Lehtimäki T, Letort S, Levin AM, Li G, Liang L, Loehr LR, London SJ, Loth DW, Manichaikul A, Marenholz I, Martinez FJ, Matheson MC, Mathias RA, Matsumoto K, Mbarek H, McArdle WL, Melbye M, Melén E, Meyers D, Michel S, Mohamdi H, Musk AW, Myers RA, Nieuwenhuis MAE, Noguchi E, O'Connor GT, Ogorodova LM, Palmer CD, Palotie A, Park JE, Pennell CE, Pershagen G, Polonikov A, Postma DS, Probst-Hensch N, Puzyrev VP, Raby BA, Raitakari OT, Ramasamy A, Rich SS, Robertson CF, Romieu I, Salam MT, Salomaa V, Schlünssen V, Scott R, Selivanova PA, Sigsgaard T, Simpson A, Siroux V, Smith LJ, Solodilova M, Standl M, Stefansson K, Strachan DP, Stricker BH, Takahashi A, Thompson PJ, Thorleifsson G, Thorsteinsdottir U, Tiesler CMT, Torgerson DG, Tsunoda T, Uitterlinden AG, van der Valk RJP, Vaysse A, Vedantam S, von Berg A, von Mutius E, Vonk JM, Waage J, Wareham NJ, Weiss ST, White WB, Wickman M, Widén E, Willemsen G, Williams LK, Wouters IM, Yang JJ, Zhao JH, Moffatt MF, Ober C, Nicolae DL. Multiancestry association study identifies new asthma risk loci that colocalize with immune-cell enhancer marks. *Nat Genet* 2018; **50**: 42-53 [PMID: 29273806 DOI: 10.1038/s41588-017-0014-7]

4 **Hao K**, Bossé Y, Nickle DC, Paré PD, Postma DS, Laviolette M, Sandford A, Hackett TL, Daley D, Hogg JC, Elliott WM, Couture C, Lamontagne M, Brandsma CA, van den Berge M, Koppelman G, Reicin AS, Nicholson DW, Malkov V, Derry JM, Suver C, Tsou JA, Kulkarni A, Zhang C, Vessey R, Opiteck GJ, Curtis SP, Timens W, Sin DD. Lung eQTLs to help reveal the molecular underpinnings of asthma. *PLoS Genet* 2012; **8**: e1003029 [PMID: 23209423 DOI: 10.1371/journal.pgen.1003029]

5 **Schwantes EA,** Evans MD, Cuskey A, Burford A, Smith JA, Lemanske RF, Jr., Jarjour NN, Mathur SK. Elevated fractional exhaled nitric oxide and blood eosinophil counts are associated with a 17q21 asthma risk allele in adult subjects. *J Asthma Allergy* 2018; **11**: 1-9 [DOI: 10.2147/jaa.s149183]

6 **Caliskan M,** Bochkov YA, Kreiner-Moller E, Bonnelykke K, Stein MM, Du G, Bisgaard H, Jackson DJ, Gern JE, Lemanske RF, Jr., Nicolae DL, Ober C. Rhinovirus wheezing illness and genetic risk of childhood-onset asthma. *N Engl J Med* 2013; **368**: 1398-1407 [DOI: 10.1056/nejmoa1211592]

7 **Smit LA**, Bouzigon E, Pin I, Siroux V, Monier F, Aschard H, Bousquet J, Gormand F, Just J, Le Moual N, Nadif R, Scheinmann P, Vervloet D, Lathrop M, Demenais F, Kauffmann F; EGEA Cooperative Group. 17q21 variants modify the association between early respiratory infections and asthma. *Eur Respir J* 2010; **36**: 57-64 [PMID: 20032010 DOI: 10.1183/09031936.00154509]

8 **Greenberg SB**. Respiratory consequences of rhinovirus infection. *Arch Intern Med* 2003; **163**: 278-284 [PMID: 12578507 DOI: 10.1001/archinte.163.3.278]

9 **Johnston SL**. The role of viral and atypical bacterial pathogens in asthma pathogenesis. *Pediatr Pulmonol Suppl* 1999; **18**: 141-143 [PMID: 10093125]

10 **Rotbart HA**, Hayden FG. Picornavirus infections: a primer for the practitioner. *Arch Fam Med* 2000; **9**: 913-920 [PMID: 11031400 DOI: 10.1001/archfami.9.9.913]

11 **Jacobs SE**, Lamson DM, St George K, Walsh TJ. Human rhinoviruses. *Clin Microbiol Rev* 2013; **26**: 135-162 [PMID: 23297263 DOI: 10.1128/CMR.00077-12]

12 **Fritz T,** Niederreiter L, Adolph T, Blumberg RS, Kaser A. Crohn's disease: NOD2, autophagy and ER stress converge. *Gut* 2009; **60**: 1580-1588 [DOI: 10.1136/gut.2009.206466]

13 **PELON W**, MOGABGAB WJ, PHILLIPS IA, PIERCE WE. A cytopathogenic agent isolated from naval recruits with mild respiratory illnesses. *Proc Soc Exp Biol Med* 1957; **94**: 262-267 [PMID: 13408229 DOI: 10.3181/00379727-94-22915]

14 **Price WH**. The isolation of a new virus associated with respiratory clinical disease in humans. *Proc Natl Acad Sci U S A* 1956; **42**: 892-896 [PMID: 16589969 DOI: 10.1073/pnas.42.12.892]

15 **Palmenberg AC**, Rathe JA, Liggett SB. Analysis of the complete genome sequences of human rhinovirus. *J Allergy Clin Immunol* 2010; **125**: 1190-9; quiz 1200-1 [PMID: 20471068 DOI: 10.1016/j.jaci.2010.04.010]

16 **Vlasak M**, Goesler I, Blaas D. Human rhinovirus type 89 variants use heparan sulfate proteoglycan for cell attachment. *J Virol* 2005; **79**: 5963-5970 [PMID: 15857982 DOI: 10.1128/JVI.79.10.5963-5970.2005]

17 **Khan AG**, Pichler J, Rosemann A, Blaas D. Human rhinovirus type 54 infection via heparan sulfate is less efficient and strictly dependent on low endosomal pH. *J Virol* 2007; **81**: 4625-4632 [PMID: 17301156 DOI: 10.1128/JVI.02160-06]

18 **Khan AG,** Pickl-Herk A, Gajdzik L, Marlovits TC, Fuchs R, Blaas D. Entry of a heparan sulphate-binding HRV8 variant strictly depends on dynamin but not on clathrin, caveolin, and flotillin. *Virology* 2011; **412**: 55-67 [DOI: 10.1016/j.virol.2010.12.042]

19 **Palmenberg AC**, Gern JE. Classification and evolution of human rhinoviruses. *Methods Mol Biol* 2015; **1221**: 1-10 [PMID: 25261302 DOI: 10.1007/978-1-4939-1571-2\_1]

20 **Bochkov YA**, Gern JE. Clinical and molecular features of human rhinovirus C. *Microbes Infect* 2012; **14**: 485-494 [PMID: 22285901 DOI: 10.1016/j.micinf.2011.12.011]

21 **Simmonds P**, McIntyre C, Savolainen-Kopra C, Tapparel C, Mackay IM, Hovi T. Proposals for the classification of human rhinovirus species C into genotypically assigned types. *J Gen Virol* 2010; **91**: 2409-2419 [PMID: 20610666 DOI: 10.1099/vir.0.023994-0]

22 **Bochkov YA**, Palmenberg AC, Lee WM, Rathe JA, Amineva SP, Sun X, Pasic TR, Jarjour NN, Liggett SB, Gern JE. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. *Nat Med* 2011; **17**: 627-632 [PMID: 21483405 DOI: 10.1038/nm.2358]

23 **Bochkov YA**, Watters K, Ashraf S, Griggs TF, Devries MK, Jackson DJ, Palmenberg AC, Gern JE. Cadherin-related family member 3, a childhood asthma susceptibility gene product, mediates rhinovirus C binding and replication. *Proc Natl Acad Sci U S A* 2015; **112**: 5485-5490 [PMID: 25848009 DOI: 10.1073/pnas.1421178112]

24 **Ruoslahti E**, Pierschbacher MD. Arg-Gly-Asp: a versatile cell recognition signal. *Cell* 1986; **44**: 517-518 [PMID: 2418980 DOI: 10.1016/0092-8674(86)90259-x]

25 **Marlin SD**, Springer TA. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). *Cell* 1987; **51**: 813-819 [PMID: 3315233 DOI: 10.1016/0092-8674(87)90104-8]

26 **Staunton DE**, Marlin SD, Stratowa C, Dustin ML, Springer TA. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. *Cell* 1988; **52**: 925-933 [PMID: 3349522 DOI: 10.1016/0092-8674(88)90434-5]

27 **Staunton DE**, Merluzzi VJ, Rothlein R, Barton R, Marlin SD, Springer TA. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. *Cell* 1989; **56**: 849-853 [PMID: 2538244 DOI: 10.1016/0092-8674(89)90689-2]

28 **Dustin ML**, Rothlein R, Bhan AK, Dinarello CA, Springer TA. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). *J Immunol* 1986; **137**: 245-254 [PMID: 3086451]

29 **Ramos TN**, Bullard DC, Barnum SR. ICAM-1: isoforms and phenotypes. *J Immunol* 2014; **192**: 4469-4474 [PMID: 24795464 DOI: 10.4049/jimmunol.1400135]

30 **Almenar-Queralt A**, Duperray A, Miles LA, Felez J, Altieri DC. Apical topography and modulation of ICAM-1 expression on activated endothelium. *Am J Pathol* 1995; **147**: 1278-1288 [PMID: 7485391]

31 **Scholz D**, Devaux B, Hirche A, Pötzsch B, Kropp B, Schaper W, Schaper J. Expression of adhesion molecules is specific and time-dependent in cytokine-stimulated endothelial cells in culture. *Cell Tissue Res* 1996; **284**: 415-423 [PMID: 8646761 DOI: 10.1007/s004410050602]

32 **Pober JS** **Jr**, Gimbrone MA, Lapierre LA, Mendrick DL, Fiers W, Rothlein R, Springer TA. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. *J immunol* 1986; **137**:1893-1896 [DOI: 10.1159/000414034]

33 **Papi A**, Johnston SL. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription. *J Biol Chem* 1999; **274**: 9707-9720 [PMID: 10092659 DOI: 10.1074/jbc.274.14.9707]

34 **Whiteman SC**, Bianco A, Knight RA, Spiteri MA. Human rhinovirus selectively modulates membranous and soluble forms of its intercellular adhesion molecule-1 (ICAM-1) receptor to promote epithelial cell infectivity. *J Biol Chem* 2003; **278**: 11954-11961 [PMID: 12551926 DOI: 10.1074/jbc.M205329200]

35 **Winther B**, Arruda E, Witek TJ, Marlin SD, Tsianco MM, Innes DJ, Hayden FG. Expression of ICAM-1 in nasal epithelium and levels of soluble ICAM-1 in nasal lavage fluid during human experimental rhinovirus infection. *Arch Otolaryngol Head Neck Surg* 2002; **128**: 131-136 [PMID: 11843719 DOI: 10.1001/archotol.128.2.131]

36 **Dieckmann M**, Dietrich MF, Herz J. Lipoprotein receptors--an evolutionarily ancient multifunctional receptor family. *Biol Chem* 2010; **391**: 1341-1363 [PMID: 20868222 DOI: 10.1515/BC.2010.129]

37 **Li Y**, Cam J, Bu G. Low-density lipoprotein receptor family: endocytosis and signal transduction. *Mol Neurobiol* 2001; **23**: 53-67 [PMID: 11642543 DOI: 10.1385/MN:23:1:53]

38 **Beglova N**, Blacklow SC. The LDL receptor: how acid pulls the trigger. *Trends Biochem Sci* 2005; **30**: 309-317 [PMID: 15950875 DOI: 10.1016/j.tibs.2005.03.007]

39 **Halbleib JM**, Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. *Genes Dev* 2006; **20**: 3199-3214 [PMID: 17158740 DOI: 10.1101/gad.1486806]

40 **Sotomayor M**, Gaudet R, Corey DP. Sorting out a promiscuous superfamily: towards cadherin connectomics. *Trends Cell Biol* 2014; **24**: 524-536 [PMID: 24794279 DOI: 10.1016/j.tcb.2014.03.007]

41 **Stokes CA**, Kaur R, Edwards MR, Mondhe M, Robinson D, Prestwich EC, Hume RD, Marshall CA, Perrie Y, O'Donnell VB, Harwood JL, Sabroe I, Parker LC. Human rhinovirus-induced inflammatory responses are inhibited by phosphatidylserine containing liposomes. *Mucosal Immunol* 2017; **10**: 829 [PMID: 28435153 DOI: 10.1038/mi.2017.40]

42 **Triantafilou K**, Vakakis E, Richer EA, Evans GL, Villiers JP, Triantafilou M. Human rhinovirus recognition in non-immune cells is mediated by Toll-like receptors and MDA-5, which trigger a synergetic pro-inflammatory immune response. *Virulence* 2011; **2**: 22-29 [PMID: 21224721 DOI: 10.4161/viru.2.1.13807]

43 **Hamparian VV,** Colonno RJ, Cooney MK, Dick EC, Gwaltney JM, Jr., Hughes JH, Jordan WS, Jr., Kapikian AZ, Mogabgab WJ, Monto A, et al. A collaborative report: rhinoviruses--extension of the numbering system from 89 to 100. *Virology* 1987; **159**: 191-192 [DOI: 10.1016/0042-6822(71)90329-1]

44 **McIntyre CL**, Knowles NJ, Simmonds P. Proposals for the classification of human rhinovirus species A, B and C into genotypically assigned types. *J Gen Virol* 2013; **94**: 1791-1806 [PMID: 23677786 DOI: 10.1099/vir.0.053686-0]

45 **Piralla A**, Rovida F, Campanini G, Rognoni V, Marchi A, Locatelli F, Gerna G. Clinical severity and molecular typing of human rhinovirus C strains during a fall outbreak affecting hospitalized patients. *J Clin Virol* 2009; **45**: 311-317 [PMID: 19473873 DOI: 10.1016/j.jcv.2009.04.016]

46 **Bizzintino J**, Lee WM, Laing IA, Vang F, Pappas T, Zhang G, Martin AC, Khoo SK, Cox DW, Geelhoed GC, McMinn PC, Goldblatt J, Gern JE, Le Souëf PN. Association between human rhinovirus C and severity of acute asthma in children. *Eur Respir J* 2011; **37**: 1037-1042 [PMID: 20693244 DOI: 10.1183/09031936.00092410]

47 **Gwaltney JM,** Jr., Hendley JO, Simon G, Jordan WS, Jr. Rhinovirus infections in an industrial population. I. The occurrence of illness. *N Engl J Med* 1966; **275**: 1261-1268. [DOI: 10.1056/nejm196612082752301]

48 **Winther B**, Gwaltney JM Jr, Mygind N, Turner RB, Hendley JO. Sites of rhinovirus recovery after point inoculation of the upper airway. *JAMA* 1986; **256**: 1763-1767 [PMID: 3018306]

49 **Sajjan U**, Wang Q, Zhao Y, Gruenert DC, Hershenson MB. Rhinovirus disrupts the barrier function of polarized airway epithelial cells. *Am J Respir Crit Care Med* 2008; **178**: 1271-1281 [PMID: 18787220 DOI: 10.1164/rccm.200801-136OC]

50 **Kennedy JL**, Turner RB, Braciale T, Heymann PW, Borish L. Pathogenesis of rhinovirus infection. *Curr Opin Virol* 2012; **2**: 287-293 [PMID: 22542099 DOI: 10.1016/j.coviro.2012.03.008]

51 **Contoli M**, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, Slater L, Lewis-Antes A, Kon OM, Holgate ST, Davies DE, Kotenko SV, Papi A, Johnston SL. Role of deficient type III interferon-lambda production in asthma exacerbations. *Nat Med* 2006; **12**: 1023-1026 [PMID: 16906156 DOI: 10.1038/nm1462]

52 **Message SD**, Laza-Stanca V, Mallia P, Parker HL, Zhu J, Kebadze T, Contoli M, Sanderson G, Kon OM, Papi A, Jeffery PK, Stanciu LA, Johnston SL. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. *Proc Natl Acad Sci U S A* 2008; **105**: 13562-13567 [PMID: 18768794 DOI: 10.1073/pnas.0804181105]

53 **Turi KN,** Shankar J, Anderson LJ, Rajan D, Gaston K, Gebretsadik T, Das SR, Stone C, Larkin EK, Rosas-Salazar C, Brunwasser SM, Moore ML, Peebles RS, Jr., Hartert TV. Infant Viral Respiratory Infection Nasal Immune-Response Patterns and Their Association with Subsequent Childhood Recurrent Wheeze. *Am J Respir Crit Care Med* 2018; **198**: 1064-73 [DOI: 10.1164/rccm.201711-2348oc]

54 **Moffatt MF**, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, Cookson WOCM; GABRIEL Consortium. A large-scale, consortium-based genomewide association study of asthma. *N Engl J Med* 2010; **363**: 1211-1221 [PMID: 20860503 DOI: 10.1056/NEJMoa0906312]

55 **Miller M**, Tam AB, Cho JY, Doherty TA, Pham A, Khorram N, Rosenthal P, Mueller JL, Hoffman HM, Suzukawa M, Niwa M, Broide DH. *ORMDL3* is an inducible lung epithelial gene regulating metalloproteases, chemokines, OAS, and ATF6. *Proc Natl Acad Sci U S A* 2012; **109**: 16648-16653 [PMID: 23011799 DOI: 10.1073/pnas.1204151109]

56 **Song DJ**, Miller M, Beppu A, Rosenthal P, Das S, Karta M, Vuong C, Mehta AK, Croft M, Broide DH. Rhinovirus Infection of *ORMDL3* Transgenic Mice Is Associated with Reduced Rhinovirus Viral Load and Airway Inflammation. *J Immunol* 2017; **199**: 2215-2224 [PMID: 28827284 DOI: 10.4049/jimmunol.1601412]

57 **Liu Y**, Bochkov YA, Eickhoff JC, Hu T, Zumwalde NA, Tan JW, Lopez C, Fichtinger PS, Reddy TR, Overmyer KA, Gumperz JE, Coon J, Mathur SK, Gern JE, Smith JA. Orosomucoid-like 3 Supports Rhinovirus Replication in Human Epithelial Cells. *Am J Respir Cell Mol Biol* 2020; **62**: 783-792 [PMID: 32078788 DOI: 10.1165/rcmb.2019-0237OC]

58 **Cantero-Recasens G**, Fandos C, Rubio-Moscardo F, Valverde MA, Vicente R. The asthma-associated *ORMDL3* gene product regulates endoplasmic reticulum-mediated calcium signaling and cellular stress. *Hum Mol Genet* 2010; **19**: 111-121 [PMID: 19819884 DOI: 10.1093/hmg/ddp471]

59 **Breslow DK**, Collins SR, Bodenmiller B, Aebersold R, Simons K, Shevchenko A, Ejsing CS, Weissman JS. Orm family proteins mediate sphingolipid homeostasis. *Nature* 2010; **463**: 1048-1053 [PMID: 20182505 DOI: 10.1038/nature08787]

60 **Ito K**, Zhang Y. Fighting the Common Cold: *ORMDL3* in the Crosshairs? *Am J Respir Cell Mol Biol* 2020; **62**: 676-677 [PMID: 32109135 DOI: 10.1165/rcmb.2020-0052ED]

61 **Zhang Y**, Willis-Owen SAG, Spiegel S, Lloyd CM, Moffatt MF, Cookson WOCM. The *ORMDL3* Asthma Gene Regulates ICAM1 and Has Multiple Effects on Cellular Inflammation. *Am J Respir Crit Care Med* 2019; **199**: 478-488 [PMID: 30339462 DOI: 10.1164/rccm.201803-0438OC]

62 **Ha SG**, Ge XN, Bahaie NS, Kang BN, Rao A, Rao SP, Sriramarao P. *ORMDL3* promotes eosinophil trafficking and activation via regulation of integrins and CD48. *Nat Commun* 2013; **4**: 2479 [PMID: 24056518 DOI: 10.1038/ncomms3479]

63 **Löser S**, Gregory LG, Zhang Y, Schaefer K, Walker SA, Buckley J, Denney L, Dean CH, Cookson WOC, Moffatt MF, Lloyd CM. Pulmonary *ORMDL3* is critical for induction of Alternaria-induced allergic airways disease. *J Allergy Clin Immunol* 2017; **139**: 1496-1507.e3 [PMID: 27623174 DOI: 10.1016/j.jaci.2016.07.033]

64 **Yoshida H**. ER stress and diseases. *FEBS J* 2007; **274**: 630-658 [PMID: 17288551 DOI: 10.1111/j.1742-4658.2007.05639.x]

65 **Song J**, Chi M, Luo X, Song Q, Xia D, Shi B, Han J. Non-Structural Protein 2B of Human Rhinovirus 16 Activates Both PERK and ATF6 Rather Than IRE1 to Trigger ER Stress. *Viruses* 2019; **11** [PMID: 30717233 DOI: 10.3390/v11020133]

66 **Jheng JR**, Ho JY, Horng JT. ER stress, autophagy, and RNA viruses. *Front Microbiol* 2014; **5**: 388 [PMID: 25140166 DOI: 10.3389/fmicb.2014.00388]

67 **Uhlig S**, Gulbins E. Sphingolipids in the lungs. *Am J Respir Crit Care Med* 2008; **178**: 1100-1114 [PMID: 18755926 DOI: 10.1164/rccm.200804-595SO]

68 **Hannun YA**, Obeid LM. Sphingolipids and their metabolism in physiology and disease. *Nat Rev Mol Cell Biol* 2018; **19**: 175-191 [PMID: 29165427 DOI: 10.1038/nrm.2017.107]

69 **Maceyka M**, Spiegel S. Sphingolipid metabolites in inflammatory disease. *Nature* 2014; **510**: 58-67 [PMID: 24899305 DOI: 10.1038/nature13475]

70 **Ammit AJ**, Hastie AT, Edsall LC, Hoffman RK, Amrani Y, Krymskaya VP, Kane SA, Peters SP, Penn RB, Spiegel S, Panettieri RA Jr. Sphingosine 1-phosphate modulates human airway smooth muscle cell functions that promote inflammation and airway remodeling in asthma. *FASEB J* 2001; **15**: 1212-1214 [PMID: 11344091 DOI: 10.1096/fj.00-0742fje]

71 **Wakita H**, Nishimura K, Tokura Y, Furukawa F, Takigawa M. Inhibitors of sphingolipid synthesis modulate interferon (IFN)-gamma-induced intercellular adhesion molecule (ICAM)-1 and human leukocyte antigen (HLA)-DR expression on cultured normal human keratinocytes: possible involvement of ceramide in biologic action of IFN-gamma. *J Invest Dermatol* 1996; **107**: 336-342 [PMID: 8751967 DOI: 10.1111/1523-1747.ep12363279]

72 **Debeuf N**, Zhakupova A, Steiner R, Van Gassen S, Deswarte K, Fayazpour F, Van Moorleghem J, Vergote K, Pavie B, Lemeire K, Hammad H, Hornemann T, Janssens S, Lambrecht BN. The *ORMDL3* asthma susceptibility gene regulates systemic ceramide levels without altering key asthma features in mice. *J Allergy Clin Immunol* 2019; **144**: 1648-1659.e9 [PMID: 31330218 DOI: 10.1016/j.jaci.2019.06.041]

73 **Miller M**, Rosenthal P, Beppu A, Gordillo R, Broide DH. Oroscomucoid like protein 3 (*ORMDL3*) transgenic mice have reduced levels of sphingolipids including sphingosine-1-phosphate and ceramide. *J Allergy Clin Immunol* 2017; **139**: 1373-1376.e4 [PMID: 27826095 DOI: 10.1016/j.jaci.2016.08.053]

74 **Ono JG**, Kim BI, Zhao Y, Christos PJ, Tesfaigzi Y, Worgall TS, Worgall S. Decreased sphingolipid synthesis in children with 17q21 asthma-risk genotypes. *J Clin Invest* 2020; **130**: 921-926 [PMID: 31929190 DOI: 10.1172/JCI130860]

75 **Bharath LP**, Ruan T, Li Y, Ravindran A, Wan X, Nhan JK, Walker ML, Deeter L, Goodrich R, Johnson E, Munday D, Mueller R, Kunz D, Jones D, Reese V, Summers SA, Babu PV, Holland WL, Zhang QJ, Abel ED, Symons JD. Ceramide-Initiated Protein Phosphatase 2A Activation Contributes to Arterial Dysfunction In Vivo. *Diabetes* 2015; **64**: 3914-3926 [PMID: 26253611 DOI: 10.2337/db15-0244]

76 **García-Ruiz C**, Colell A, Marí M, Morales A, Fernández-Checa JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. *J Biol Chem* 1997; **272**: 11369-11377 [PMID: 9111045 DOI: 10.1074/jbc.272.17.11369]

77 **Kiefer K**, Casas J, García-López R, Vicente R. Ceramide Imbalance and Impaired TLR4-Mediated Autophagy in BMDM of an *ORMDL3*-Overexpressing Mouse Model. *Int J Mol Sci* 2019; **20** [PMID: 30897694 DOI: 10.3390/ijms20061391]

78 **Goetzl EJ**, Rosen H. Regulation of immunity by lysosphingolipids and their G protein-coupled receptors. *J Clin Invest* 2004; **114**: 1531-1537 [PMID: 15578083 DOI: 10.1172/JCI23704]

79 **Chalfant CE**, Spiegel S. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling. *J Cell Sci* 2005; **118**: 4605-4612 [PMID: 16219683 DOI: 10.1242/jcs.02637]

80 **Jolly PS**, Bektas M, Olivera A, Gonzalez-Espinosa C, Proia RL, Rivera J, Milstien S, Spiegel S. Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. *J Exp Med* 2004; **199**: 959-970 [PMID: 15067032 DOI: 10.1084/jem.20030680]

81 **Oskeritzian CA**, Milstien S, Spiegel S. Sphingosine-1-phosphate in allergic responses, asthma and anaphylaxis. *Pharmacol Ther* 2007; **115**: 390-399 [PMID: 17669501 DOI: 10.1016/j.pharmthera.2007.05.011]

82 **Ono JG**, Worgall TS, Worgall S. Airway reactivity and sphingolipids-implications for childhood asthma. *Mol Cell Pediatr* 2015; **2**: 13 [PMID: 26637347 DOI: 10.1186/s40348-015-0025-3]

83 **Grassmé H**, Riehle A, Wilker B, Gulbins E. Rhinoviruses infect human epithelial cells via ceramide-enriched membrane platforms. *J Biol Chem* 2005; **280**: 26256-26262 [PMID: 15888438 DOI: 10.1074/jbc.M500835200]

84 **Mousnier A**, Swieboda D, Pinto A, Guedán A, Rogers AV, Walton R, Johnston SL, Solari R. Human rhinovirus 16 causes Golgi apparatus fragmentation without blocking protein secretion. *J Virol* 2014; **88**: 11671-11685 [PMID: 25100828 DOI: 10.1128/JVI.01170-14]

85 **Roulin PS**, Lötzerich M, Torta F, Tanner LB, van Kuppeveld FJ, Wenk MR, Greber UF. Rhinovirus uses a phosphatidylinositol 4-phosphate/cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface. *Cell Host Microbe* 2014; **16**: 677-690 [PMID: 25525797 DOI: 10.1016/j.chom.2014.10.003]

86 **Yetkin-Arik B**, Vogels IMC, Nowak-Sliwinska P, Weiss A, Houtkooper RH, Van Noorden CJF, Klaassen I, Schlingemann RO. The role of glycolysis and mitochondrial respiration in the formation and functioning of endothelial tip cells during angiogenesis. *Sci Rep* 2019; **9**: 12608 [PMID: 31471554 DOI: 10.1038/s41598-019-48676-2]

87 **Qian X**, Aboushousha R, van de Wetering C, Chia SB, Amiel E, Schneider RW, van der Velden JLJ, Lahue KG, Hoagland DA, Casey DT, Daphtary N, Ather JL, Randall MJ, Aliyeva M, Black KE, Chapman DG, Lundblad LKA, McMillan DH, Dixon AE, Anathy V, Irvin CG, Poynter ME, Wouters EFM, Vacek PM, Henket M, Schleich F, Louis R, van der Vliet A, Janssen-Heininger YMW. IL-1/inhibitory κB kinase ε-induced glycolysis augment epithelial effector function and promote allergic airways disease. *J Allergy Clin Immunol* 2018; **142**: 435-450.e10 [PMID: 29108965 DOI: 10.1016/j.jaci.2017.08.043]

88 **Ostroukhova M**, Goplen N, Karim MZ, Michalec L, Guo L, Liang Q, Alam R. The role of low-level lactate production in airway inflammation in asthma. *Am J Physiol Lung Cell Mol Physiol* 2012; **302**: L300-L307 [PMID: 22080752 DOI: 10.1152/ajplung.00221.2011]

89 **Roncoroni AJ**, Adrougué HJ, De Obrutsky CW, Marchisio ML, Herrera MR. Metabolic acidosis in status asthmaticus. *Respiration* 1976; **33**: 85-94 [PMID: 778959 DOI: 10.1159/000193721]

90 **Xu YD**, Cui JM, Wang Y, Yin LM, Gao CK, Liu YY, Yang YQ. The early asthmatic response is associated with glycolysis, calcium binding and mitochondria activity as revealed by proteomic analysis in rats. *Respir Res* 2010; **11**: 107 [PMID: 20691077 DOI: 10.1186/1465-9921-11-107]

91 **Passalacqua KD**, Lu J, Goodfellow I, Kolawole AO, Arche JR, Maddox RJ, Carnahan KE, O'Riordan MXD, Wobus CE. Glycolysis Is an Intrinsic Factor for Optimal Replication of a Norovirus. *mBio* 2019; **10** [PMID: 30862747 DOI: 10.1128/mBio.02175-18]

92 **Edukulla R**, Rehn KL, Liu B, McAlees JW, Hershey GK, Wang YH, Lewkowich I, Lindsley AW. Intratracheal myriocin enhances allergen-induced Th2 inflammation and airway hyper-responsiveness. *Immun Inflamm Dis* 2016; **4**: 248-262 [PMID: 27621809 DOI: 10.1002/iid3.110]

93 **Stockmann-Juvala H**, Savolainen K. A review of the toxic effects and mechanisms of action of fumonisin B1. *Hum Exp Toxicol* 2008; **27**: 799-809 [PMID: 19244287 DOI: 10.1177/0960327108099525]

94 **Masini E**, Giannini L, Nistri S, Cinci L, Mastroianni R, Xu W, Comhair SA, Li D, Cuzzocrea S, Matuschak GM, Salvemini D. Ceramide: a key signaling molecule in a Guinea pig model of allergic asthmatic response and airway inflammation. *J Pharmacol Exp Ther* 2008; **324**: 548-557 [PMID: 18042827 DOI: 10.1124/jpet.107.131565]

95 **Morad SA**, Cabot MC. Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications. *Biochim Biophys Acta* 2015; **1851**: 1134-1145 [PMID: 25964209 DOI: 10.1016/j.bbalip.2015.05.001]

96 **Perez B**, Henriquez C, Sarmiento J, Morales N, Folch H, Galesio JS, Uberti B, Morán G. Tamoxifen as a new therapeutic tool for neutrophilic lung inflammation. *Respirology* 2016; **21**: 112-118 [PMID: 26510482 DOI: 10.1111/resp.12664]

97 **Baer A**, Colon-Moran W, Bhattarai N. Characterization of the effects of immunomodulatory drug fingolimod (FTY720) on human T cell receptor signaling pathways. *Sci Rep* 2018; **8**: 10910 [PMID: 30026610 DOI: 10.1038/s41598-018-29355-0]

98 **Brinkmann V**, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. *Am J Transplant* 2004; **4**: 1019-1025 [PMID: 15196057 DOI: 10.1111/j.1600-6143.2004.00476.x]

99 **Delgado A**, Casas J, Llebaria A, Abad JL, Fabrias G. Inhibitors of sphingolipid metabolism enzymes. *Biochim Biophys Acta* 2006; **1758**: 1957-1977 [PMID: 17049336 DOI: 10.1016/j.bbamem.2006.08.017]

100 **Babenko NA**, Kharchenko VS. Effects of inhibitors of key enzymes of sphingolipid metabolism on insulin-induced glucose uptake and glycogen synthesis in liver cells of old rats. *Biochemistry (Mosc)* 2015; **80**: 104-112 [PMID: 25754045 DOI: 10.1134/S0006297915010125]

101 **Upadhyay S**, Palmberg L. Air-Liquid Interface: Relevant In Vitro Models for Investigating Air Pollutant-Induced Pulmonary Toxicity. *Toxicol Sci* 2018; **164**: 21-30 [PMID: 29534242 DOI: 10.1093/toxsci/kfy053]

102 **Wijman JG**, de Leeuw PP, Moezelaar R, Zwietering MH, Abee T. Air-liquid interface biofilms of Bacillus cereus: formation, sporulation, and dispersion. *Appl Environ Microbiol* 2007; **73**: 1481-1488 [PMID: 17209076 DOI: 10.1128/AEM.01781-06]

103 **Caves EA**, Cook SA, Lee N, Stoltz D, Watkins S, Shair KHY. Air-Liquid Interface Method To Study Epstein-Barr Virus Pathogenesis in Nasopharyngeal Epithelial Cells. *mSphere* 2018; **3** [PMID: 30021875 DOI: 10.1128/mSphere.00152-18]

104 **Nakauchi M**, Nagata N, Takayama I, Saito S, Kubo H, Kaida A, Oba K, Odagiri T, Kageyama T. Propagation of Rhinovirus C in Differentiated Immortalized Human Airway HBEC3-KT Epithelial Cells. *Viruses* 2019; **11** [PMID: 30836639 DOI: 10.3390/v11030216]

105 **Erpenbeck VJ**, Hohlfeld JM, Volkmann B, Hagenberg A, Geldmacher H, Braun A, Krug N. Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. *J Allergy Clin Immunol* 2003; **111**: 1319-1327 [PMID: 12789235 DOI: 10.1067/mai.2003.1485]

106 **Torras N**, García-Díaz M, Fernández-Majada V, Martínez E. Mimicking Epithelial Tissues in Three-Dimensional Cell Culture Models. *Front Bioeng Biotechnol* 2018; **6**: 197 [PMID: 30619844 DOI: 10.3389/fbioe.2018.00197]

107 **Allen M**, Heinzmann A, Noguchi E, Abecasis G, Broxholme J, Ponting CP, Bhattacharyya S, Tinsley J, Zhang Y, Holt R, Jones EY, Lench N, Carey A, Jones H, Dickens NJ, Dimon C, Nicholls R, Baker C, Xue L, Townsend E, Kabesch M, Weiland SK, Carr D, von Mutius E, Adcock IM, Barnes PJ, Lathrop GM, Edwards M, Moffatt MF, Cookson WO. Positional cloning of a novel gene influencing asthma from chromosome 2q14. *Nat Genet* 2003; **35**: 258-263 [PMID: 14566338 DOI: 10.1038/ng1256]

108 **Zhang Y**, Poobalasingam T, Yates LL, Walker SA, Taylor MS, Chessum L, Harrison J, Tsaprouni L, Adcock IM, Lloyd CM, Cookson WO, Moffatt MF, Dean CH. Manipulation of dipeptidylpeptidase 10 in mouse and human *in vivo* and *in vitro* models indicates a protective role in asthma. *Dis Model Mech* 2018; **11** [PMID: 29361513 DOI: 10.1242/dmm.031369]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 17, 2021

**First decision:** April 6, 2021

**Article in press:** August 23, 2021

**Specialty type:** Critical care medicine

**Country/Territory of origin:** United Kingdom

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Alberca RW, Rolla G **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Li X

**Table 1 Orosomucoid-like protein 3 roles in regulating human rhinovirus infection**

|  |  |  |
| --- | --- | --- |
| **Regulating molecules and processes** | **The roles in human rhinovirus infection** | **Ref.** |
| ICAM1 | *ORMDL3* regulates ICAM1 expression for influencing HRV adhesion and entrance and viral load | [56,61,62] |
| ER stress | *ORMDL3* regulates ER stress and the ER stress can induce PERK and IRE1 pathways that affect HRV infection | [61,63,65] |
| Ceramide and S1P | *ORMDL3* regulates ceramide and S1P levels. S1P and ceramide are responsible for cell survival, proliferation, apoptosis, differentiation and cell-cycle arrest; they also affect ICAM1 expression | [55,61,71,72,77] |
| ER-Golgi interface | HRV can both fragment the Golgi apparatus and block secretion. *ORMDL3* regulates ER-Golgi interface through ER stress and sphingolipid metabolism | [61,84,85] |
| Glycolysis | *ORMDL3* regulates glycolysis. Glycolysis can determine the extent of replication of HRVs in cells | [61,91] |

ICAM1: Intercellular adhesion molecule 1; *ORMDL3*: Orosomucoid-like protein 3; HRV: Human rhinovirus; ER: Endoplasmic reticulum; S1P: Sphingosine-1-phosphate.

**Table 2 The models for studying interaction of host and environmental factors**

|  |  |  |
| --- | --- | --- |
| **The available models** | **Advantages** | **Disadvantages** |
| Monolayer cell models | Simplistic model; Easy to culture within short times | Cells underneath the medium, no connection to other types of cells and no tight junctions; Non-optimal physiologic response; The growth kinetics of bacteria, fungal or virus on monolayer are known to be different from human body |
| Air liquid interface model | Polarized differentiated airway epithelium containing ciliated epithelial cells, basal cells and mucus producing cells, mimicking human epithelium; It can be co-cultured with pathogens; Respiratory virus is known to show similar replication kinetics as in human body |  |
| 3D human lung spheroid model | 3D multicellular spheroids are small, tightly bound cellular aggregates that tend to form when cells are maintained under non-adherent conditions; Other cell types such as fibroblasts can be incorporated and can be co-cultured with pathogens |  |
| Animal models | *In vivo* | Have ethical issues and many results cannot be replicated in human studies; High cost; Time consuming, not applicable to high-throughput studies |

3D: Three-dimensional.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**